Impact of Vitamin D Supplementation on Cholesterol Levels
Study Overview
In a 2017 study, researchers investigated the effects of dietary and ultraviolet light (UV)-derived vitamin D on blood levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The results indicated that vitamin D supplementation, regardless of its source, does not enhance the cholesterol or triglyceride profiles in patients with vitamin D deficiency.
Vitamin D’s Role in Health
While vitamin D supplementation has demonstrated benefits in treating and preventing bone-related diseases, its effectiveness for other health conditions remains debated. It is suggested that the source of vitamin D—whether dietary or synthesized in skin cells through UVB exposure—may contribute to the varying outcomes reported in different studies.
Previous Findings
Earlier research has shown that patients with low levels of the vitamin D metabolite 25-hydroxyvitamin D (25(OH)D) tend to have elevated LDL cholesterol levels, decreased HDL cholesterol levels, and increased triglyceride levels. This lipid profile is linked to several health complications. Furthermore, studies have indicated that restoring 25(OH)D levels through oral vitamin D administration does not influence fat and cholesterol levels.
Details of the 2017 Study
Study Design
The 2017 study, published in the American Journal of Clinical Nutrition, compared the effects of oral vitamin D supplementation and UVB exposure on lipid profiles. Adult participants aged 70 years or younger with 25(OH)D levels below 20 ng/mL were recruited. The study spanned six months, with participants divided into two groups: one receiving oral vitamin D3 (OVD) and the other exposed to UVB light.
Methods of Supplementation
Participants in the OVD group were given an 8-week supply of forty 10,000 IU vitamin D3 capsules, instructed to take five capsules weekly. If their 25(OH)D levels remained below 35 ng/mL after 8 weeks, they received an additional one-week supply before each follow-up. The UVB group underwent UVB exposure across their bodies, except for covered areas, with initial exposure times varying based on Fitzpatrick skin types. Subsequent exposure times increased by 10% as tolerated, up to a maximum of 4.5 minutes, with an average of two sessions per week for 8 weeks.
Participant Demographics and Outcomes
A total of 148 subjects participated in the study, with 73 assigned to the oral vitamin D group and 75 to the UVB group. Among these, 60 from the OVD group and 58 from the UVB group completed at least 8 weeks of treatment. At the start of the study, participants in the OVD group were, on average, 5.5 years older and had lower fat levels compared to the UVB group.
After 8 weeks, the average 25(OH)D level increased by 33 ng/mL in the OVD group and 14 ng/mL in the UVB group, with a high percentage of participants in both groups requiring additional treatment. However, changes in HDL, LDL, and total cholesterol levels were not statistically significant between the groups.
Gene Activity and Adverse Events
The study also evaluated the activity of vitamin D-related genes, revealing similar activity levels for both groups. Notably, interferon-alpha and interferon-gamma activity significantly increased in the OVD group, while it decreased in the UVB group across both blood and skin biopsy samples. Common adverse events included gastrointestinal distress and constipation, with skin irritation and rash being more prevalent in the UVB group compared to the OVD group.
Conclusions and Future Research Directions
The findings suggest that vitamin D supplementation, regardless of its source, does not improve cholesterol and fat profiles in patients with vitamin D deficiency. However, dietary and UVB-derived vitamin D may influence immune-related genes differently. As the study did not monitor participants’ dietary intake or sun exposure, the impact of daily vitamin D sources remains uncertain. Additionally, the absence of placebo groups limits the assessment of the benefits of vitamin D supplementation compared to no treatment. Given the high proportion of patients needing further treatment after 8 weeks, future research should consider longer treatment durations and more frequent dosing to evaluate potential health benefits effectively.